TO OPTIMIZED THE DISSOLUTION AND SOLUBILITY PROPERTY …

www.wjpr.net Vol 8, Issue 8, 2019.

1048

Ompal et al. World Journal of Pharmaceutical Research

TO OPTIMIZED THE DISSOLUTION AND SOLUBILITY PROPERTY

OF CELECOXIB BY THE PREPARATION OF LIQUISOLID

COMPACT

Ompal*1, Dr. Sarveh Jain Malviya

2 and Dr. Puspendra Kumar Jain

1

2(Director) Onions Healthcare Pvt. Ltd, Mohali, Chandigarh.

1(Dean Cum Prof.), IIMT College of Pharmacy, Greater Nouns.

ABSTRACT

“Liquisolid” technique is a novel and capable to development of

dissolution rate and solubility of water-insoluble drugs like piroxicam,

indomethacin, olmesartan, valsartan, and rosuvastatin. It is also used

for the sustained and immediate release of the formulation. Liquisolid

compact contains liquid medications in powder form. The liquisolid

technique is the most competitive process for the formulation of water-

insoluble and water- soluble agents. The liquisolid compact is an

admixture of the drug, nonvolatile solvent, coating material, carrier

material. In this technique carrier and coating substance must be in a

ratio of 3:1, 5:1, 7:1, 10:1, 15:1, 20:1, is mixed into the nonvolatile

solvent. Dissolution Test of celecoxib was carried out by using a type 2 basket method

(dissolution medium 900 ml, 7.4 pH of phosphate buffer, 100 r/m, 37±0.5ºC), to simulate the

stomach or intestine solution. In this study, develop the solubility and dissolution properties

of the celecoxib was investigated. Development of solubility and dissolution of the agents by

use of non-volatile solvents (PEG 400, PEG200, and GLYCEROL), causes enhanced

wettability and improves wettability leads to enhance solubility. Thereby it builds up the

bioavailability. The liquisolid compact also contains carrier material and coating material

(excipients). By using the liquisolid technique, solubility and dissolution rate is increased and

immediate and sustained drug formulation can be developed for water-soluble drugs.

KEYWORDS: Celecoxib, Liquisolid compact, Bioavailability, nonvolatile solvent,

excipients.

World Journal of Pharmaceutical Research SJIF Impact Factor 8.074

Volume 8, Issue 8, 1048-1067. Research Article ISSN 2277– 7105

Article Received on

21 May 2019,

Revised on 12 June 2019,

Accepted on 01 July 2019,

DOI: 10.20959/wjpr20198-15371

*Corresponding Author

Ompal

(Dean Cum Prof.), IIMT

College of Pharmacy, Greater

Nouns.


1049


INTRODUCTION

Nowadays, one of the main challenging tasks for all pharmaceutical companies in the

development of poor solubility of drug.

A drug belonging to BCS class II and Class IV has a low solubility and dissolution rate that

lead to poor bioavailability. lyophilization, Micronisation, co-solvency, and complexing

agents are the process used to improve the dissolution rate of BCS class-II drugs. Many

techniques are used to overcome these problems, the liquisolid technique is one of the most

victorious actions that develop bioavailability of BCS class II and Class IV.[1,2]

“Liquisolid

technology” is also known as “powder solution technology”.

In this technology, the oral route of the drug is preferred because it provides patients with

compliance and takes a low medicine production cost.

This technique is capable to change the dissolution rate of drugs, in the liquisolid technology

lipophilic or water-insoluble solid drugs dissolved in nonvolatile solvents and conversation of

liquid drugs into the non-adherent, free following, dry looking and easily compressed with

excipients.

The drug is present in the form of liquid medication and solubilized in a dispersed state.

Liquid medication leads to enhance surface area and wetting properties of the drug and it is

beneficial for dissolution rate of the capsules. A liquisolid drug shows improved dissolution

properties of a water-insoluble drug. These improved dissolution properties lead to better

bioavailability of the drug.[3]

Advantages of Liquisolid Compact

1. Liquisolid techniques optimized the rapid release of capsules and tablets.

2. The production of liquisolid compact in industry is possible.

3. Bioavailability of the liquisolid drug is improved as compare to conventional drug.

4. Liquisolid formulation production cost is very low when compare to the soft and hard

gelatin capsules.

5. Liquisolid technique optimized the flowability and compressibility of powder.

6. Manufacturing process of a liquisolid formulation is same as conventional tablet

formulation.

7. Optimized solubility and dissolution properties of a drug.


1050


8. Industrially applicable.

9. In the liquisolid technique, the operation like micronization, nanonization of particles is

not involved.

10. Liquisolid technique is very simple to perform.

11. Liquisolid technique is widely used to liquid lipophilic drugs or oily drugs.[4]

Disadvantages of Liquisolid Compact

1) In the liquisolid technique needs of excipients like non-volatile solvents, coating material,

carrier material, disintegrants.

2) Liquisolid compact does not apply to high dose. They apply only for less than 100mg

drugs.[5]

3) Liquisolid compact is formed by high amount of excipients (carrier and coating material)

for maintaining a solubility and compatibility of drug. Sometime the mass of the

excipients is very high at that time the tablet and capsule is hard to engulf.[6]

MATERIALS AND METHOD

Materials– Many material are used to received celecoxib formulation, i.e. celecoxib powder

from Hongkong Xinrunde chemical co.ltd., and Potassium dihydrogen-o phosphate (Signet

Chemical Corp. Pvt. Ltd., Mumbai), Sodium hydroxide pellets (Fisher Chemical Ltd.,

Ahmedabad), Ethanol (Changshu Yanguan Chemical, China), Methanol (Fisher Chemical

Ltd., Ahmedabad), Acetone (Thomas Baker), n-octanol (Molychem), PEG 200 and PEG400

(Fisher scientific), Glycerol (Loba Cheme), Span20, Tween20 and Tween80 (CDH Fine),

Span80 (SD Fine), Propylene Glycol (Thomas Baker), Kolliphor-EL ( BASF Pharma).

Equipments- Dissolution (Orchid Scientific) UV-Visible spectrophotometer (Shimadzu UV-

1800, Dt (PERFIT India) Electronic weighing balance (Shimadzu) Hot air oven (Colton)

Sonicator (PCI Analytic) Magnetic stirrer or Mechanical stirrer and Hot plate (REMI

apparatus) Melting point (PERFIT) FTIR Spectrophotometer (Bruker), Eppendorf tubes

(Tarsons Products Pvt. Ltd., Kolkata, India), Vortex-type mixer, (Vortex-type mixer),

Cooling centrifuge (REMI Equipment).

Method

Preformulation Study- The first learning phase is known as preformulation. Preformulation

study is the phase of research and development of drug in which determine the physical and


1051


chemical properties of drug with or without excipients to develop an effective, safe, and new

dosage form. The preformulation study is done prior to the development phase.

In the preformulation study, we determined the organoleptic character of drug, melting point,

solubility study, FTIR spectroscopy, determination of λmax, a standard curve of a drug,

partition coefficient.

Melting point– Take a thin glass capillary tube, which has one end open and the other end

sealed. Dip the open end of the tube into a pile of a drug. After that glass capillary tube and

thermometer were placed at a specific site in the melting point apparatus. When the temp.

was increased the drug started to melt in the capillary tube was noted down.

FTIR Spectroscopy – FT-IR (Fourier transform infrared) spectrum gives a information

about the group present in particular compound and structural analysis. The potassium

bromide technique was employed because potassium bromide (KBr) has no own absorption

in fundamental region. KBr disc was prepared by using 2mg of celecoxib with KBr, and

triturating in a mortar glass, and after that the KBr disc was placed in FTIR sample holder

and scanned by the FTIR under the range of 400 - 4000cm-1.[7]

Partition Coefficient of Drug – The standard solution of celecoxib was scanned in the

wavelength region of 200-400 nm and the wavelength of maximum absorption (λmax) was

found to be 252nm by using UV- spectrophotometer. A 2 µg/ml solution of celecoxib in

methanol was scanned in the range of 200-400 nm.

Shake-flask method

The partition coefficient determination study was performed by using the shake flask method.

Excess amounts of the drug (celecoxib) mixed in 10 ml of two solvents (n-octanol: Water)

together (1:1) and placed for 24 h. After 24 h, the two layers were separated and centrifuge

for 30 min’s at 15,000 rpm. The absorbance was taken in a UV spectrophotometer at the

respective λ max after appropriate dilution.

Estimation of Celecoxib by UV-visible spectrophotometer

The standard stock solution of celecoxib (10mg/10ml) was prepared in methanol. This

solution was diluted with methanol, to obtain various dilutions from 2-18µg/ml. The

absorbance of solutions was recorded at 252 nm against methanol as blank using a UV-

visible spectrophotometer and the standard curve was plotted against concentration. From the


1052


calibration curve intercept, slope, straight line equation and correlation coefficient were

obtained.

Solubility study

For spontaneous interaction of two or more substance to form a homogenous molecular

dispersion is called solubility. Excess quantity of drug was taken in thoroughly cleaned

culture tubes containing 2 ml of different solvents (methanol, Acetone, 0.1NHCL, water, pH

6.8, pH 7.4) and nonsolvent (PEG 200, PEG 400, kolliphor EL) and test tubes were tightly

closed. These test tubes were shaking on a water bath shaker at 25ᵒC for 24 h at room

temperature. After 24 h each sample was centrifuged 15,000 rpm and the supernatant was

withdrawal. After that supernatant was filtered and filtrates was suitably diluted and

determined spectrophotometrically.

Determination of loading factor

Weight 5g of powder (carrier material and coating material) and placed on metal plate with a

polished surface. After that metal plate tilted slowly until the carrier or coating material start

to slide and create an angle. Angle of slide at 33ᵒ shows the optimal flow of powder. The ɸ

value of carrier and coating material plotted against corresponding 33ᵒ ɸ-value is required for

the preparation of liquisolid compact.

ɸ value = weight of liquid/weight of solid

Lf=ɸ carrier +ɸ coating (1/R)

Loading factor is determine with the help of ɸ value of carrier and coating material. R is the

ratio of coating and carrier material. The ratio of R should be 15:1, 10:1, 7:1, 5:1, and 3:1.

After that the value of loading factor was used to calculate the carrier and coating material by

using Lf=W/Q and R=Q/q.[8]

W= weight of liquid medication

Q= weight of carrier substance

q=weight of coating substance


1053


Selection of ratio of solvent, carrier and coating material

Composition of the liquisolid compacts

Formulation

code

Drug

concentration in

liquid medication

R

value

Loading

factor

Liquid

vehicle

(PEG 400)

Carrier

(avicel ph

102)

Coating

(aerosil

200)

Total

weight

L1 60 3 0.373 166 443.85 147.95 857.8

L2 60 5 0.264 166 628.79 125.79 920.58

L3 60 7 0.217 166 764.98 109.28 1040.26

L4 50 3 0.373 200 534.76 178.26 1013.02

L5 50 5 0.264 200 754.71 150.94 1105.65

L6 50 7 0.217 200 921.66 131.67 1253.33

L7 40 3 0.374 250 668.45 222.82 1241.27

L8 40 5 0.264 250 946.97 189.394 1336.364

L9 40 7 0.217 250 1152.07 164.58 1516.65

L10 30 3 0.374 333 890.37 296.79 1620.16

L11 30 5 0.264 333 1261.36 252.27 1846.63

L12 30 7 0.217 333 1534.56 219.22 2086.78

Angle of repose

Maximum angle of inclination till a block do not get slide on the sliding surface is called

angle of slide. It is related to the surface area and density coefficient.

Tan (angle of repose) θ = (height of pile) h / r (radius of pile).

If the angle of repose is more than 35 then flow property considers as poor and less than 25

shows the excellent flow.

Method –The sample was poured by a funnel to make a cone. Allow to flow easily through

the funnel under gravity, stop pouring the powder when the pile reaches at predetermined

height and base. After that a graph sheet was taken to determine the area of pile and height of

the pile, by using a height and base of pile to evaluate angle of repose.

Bulk density

Bulk volume is also known as volumetric density, it’s the quantitative relation between the

mass of the powder and bulk volume of powder. Its depend on particle shape, density of the

powder, and arrangement of powder particle in a graduated cylinder and bulking properties of

powder depends on the preparation and storage of the sample.

Unit of bulk density = g/ml

International unit of bulk density = kilogram per cubic meter (kg/m3).


1054


Bulk density = mass of the powder / bulk volume of powder.

Method- It was measured by pouring the adequate amount of powder into a measuring

cylinder and the initial volume was noted. The initial volume of powder is known as bulk

volume of the powder. From this, the bulk density of the powder was calculated.

Tapped density: Tapped density is defined as the quantitative relation between the mass of

bulk powder and tapped volume of powder. Tapped density is obtained by mechanically

tapping of measuring cylinder.

ρt = M / Vt

Where

ρt = Tapped density

M = Mass of blend in g.

Vt = Tapped volume of blend powder in cm.

Method – pour the sample into a measuring cylinder and first the measuring cylinder tapped

for five hundred times and volume of the powder was noted and after that again tapping the

measuring cylinder for seven hundred fifty times and volume was reported. The difference

between this two volume should be less than two.

Carr’s index: Carr’s Index indicates the compressibility of powder, flowability of powder.

Carr’s Index is a measure of the flow of powder to be compressed. Carr’s index is determine

from the volume of bulk and tapped density. It is calculated by-

Carr’s Index = tapped density (ρt) – bulk density (ρb)/tapped density (ρt) *100,

A Carr’s index less than 25 is considered of good flowability.

Hausner’s ratio - It is defined as the quantitative relation between tapped density and bulk

density is known as Hausner’s ratio = Tapped density/ Bulk density

A Hausner ratio greater than 1.25 is considered of poor flowability.[9]

Preparation of liquisolid compact - A calculated amount of drug substance ought to be

spread within the non-volatile solvent system (PEG-400) termed as a liquid vehicle. With a

different drug vehicle ratio add an adequate amount of carrier and coating material in a

mortar and mixed them. Binary mixtures of drug, non-volatile solvent, and excipients. Fill the

capsule with a binary mixture by employing a manual capsule filling machine.


1055


RESULTS AND DISCUSSION

Result of preformulation

Preformulation studies aim to consider the physical and chemical properties of a drug

substance. The selected drug celecoxib was subjected for investigation of physical

characterization parameters such as:

Organoleptic properties

Melting point

UV-visible spectra

Partition coefficient

Solubility

FT-IR spectra

Organoleptic properties

The fundamental properties of the pure drug were tested as appearance, color, and odor. It

was noticed a powder was white and have no odor.

Table 1: Organoleptic properties of Celecoxib.

S. No. Test Specification Observation

1. Appearance Fine powder Fine powder

2. Colour White White

3. Odor Odorless Odorless

Melting point Determination

The melting point of the celecoxib was measured by capillary tube method.

Table 2: Melting point.

Drug Observed value Reference value

Celecoxib 152˚C±0.279 157-159˚C

Discussion: The melting point of celecoxib was found to be 152˚C±0.279, which is of the

pure drug. Hence drug sample was free from any type of impurities.


1056


UV Spectroscopy

Determination of absorption maxima in methanol

Figure 1: Spectrum graph of celecoxib to detect the λmax under the scan range from 200-

400.

Discussion- Absorption maxima of celecoxib were found to be at 252 nm similar to reported.

Preparation of standard curve of celecoxib in methanol

Table 3: UV Calibration data celecoxib in methanol (λmax = 252nm).

S. No. Concentration (µg/ml) Absorbance (mean±SD)

1 2 0.138±0.001

2 4 0.244±0.001

3 6 0.334±0.002

4 8 0.446±0.006

5 10 0.548±0.006

6 12 0.648±0.004

7 14 0.759±0.002

8 16 0.870±0.011

9 18 0.978±0.01


1057


Figure 2: Standard calibration curve of celecoxib in methanol (λmax = 252nm).

Table 4: Result of regression analysis of UV Method for estimation of celecoxib.

Statistical Parameters Results

λmax 252nm

Regression Equation Y=0.052x+0.027

Slope (b) 0.052

Intercept(c) 0.027

Correlation coefficient (r2) 0.999

Discussion: The calibration curve for celecoxib was obtained by using the 2 to 18 µg/ml

concentration of celecoxib in Methanol. The absorbance was measured at 252nm. The

calibration curve of celecoxib as shown in the graph indicated the regression equation Y=

0.052x+0.027 and R2 value 0.999, which shows good linearity as in Table 4 and Figure 2.

Partition coefficient

Partition coefficient determine by using a separating funnel. If the value of log p greator than

one that means drug is lipophilic in nature and less than one indicates the hydrophilic in

nature.

Concentration of the drug in non- aqueous phase

K o/w =

Concentration of drug in aqueous phase


1058


Table 5: Determination of partition coefficient.

Partition coefficient of drug Solvent system Log P value

Celecoxib Water : n-octanol 3.321±0.477

Discussion: The value of partition coefficient of celecoxib in water: n-octanol was found to

be 3.321±0.477; this indicates that the drug is lipophilic in nature.

Solubility Studies

The solubility of the drug in different solvents was carried out to screen for the components

to be employed for formulation development. Analysis of the drug was carried out on UV-

spectrophotometer at 252 nm.

Table 6: Solubility studies of celecoxib in solvents and non-volatile solvent.

S. no. Name of solvent Solubility of celecoxib (mg/ml ± std)

1 Water 0.068±0.0010

2 Methanol 18.3205±0.7106

3 Acetone 5.314103±0.0967

4 pH-6.8 0.0183±0.0015

5 pH7.4 0.0085±0.0002

6 0.1N HCL 0.0056±0.0002

*Each value is mean of three independent determinations

Figure 3: Solubility of celecoxib in different solvents.

Discussion: From the above data, it is seen that celecoxib is highly soluble in acetone,

methanol. Table 6, and Figure 3.


1059


Table 7: Solubility of non solvent.

S. NO. Name of non-solvent Mean±std

1 PEG 200 63.590±0.294

2 PEG400 64.295±0.400

3 GLYCEROL 0.295±0.0131

4 SPAN 20 63.974±0.728

5 SPAN80 18.75±0.408

6 TWEEN 20 50.641±0.728

7 TWEEN 80 56.026±0.618

8 PROPYLENE GLYCOL 34.487±0.484

9 KOLLIPHOR (EL) 43.205±0.909

*Each value is mean of three independent determinations

Figure 4: Soloubility of Celecoxib with different solvent and non volatile solvent.

Discussion: From the above data, it is seen that celecoxib is highly soluble in PEG200,

PEG400 as followed by SPAN 20.Table 7 and Figure 4.

FTIR analysis of pure drug

FT-IR analysis detects the selective absorption of light by the vibration modes of precise

chemical bonds in the sample. The FT-IR spectrum of celecoxib is shown in Figure 5 and the

interpretation of data is given in Table 8.


1060


Figure 5: FTIR spectrum of celecoxib.

Table 8: Interpretation of FTIR spectrum of celecoxib.

Discussion: The observed FT-IR spectrum confirmed and identified the presence of

functional groups and the purity of the drug. Table 8, and figure 5.

Angle of slide

Table 9: Characterstics of carrier and coating material.

ANGLE OF SLIDE ᶲ VALUE

Avicel PH 102 Aerosil 200 Avicel PH 102 Aerosil 200

37 32 0 0

33 31 0.5 0.46

26 32 0.74 0.67

27 33 0.92 0.82

25 35 1.0 1.0

22 34 1.15 1.25

Reported peak(cm-1)

Observed peak(cm-1

) Functional group

1164 1164.18 S=0 symmetric

1347 1346.36 S=0 asymmetric

3232 3236.66 N-H stretching


1061


Figure 6: Determination of ɸ value.

Discussion: According to a procedure in PEG400 the ɸ value was found to be 0.5 for Avicel

ph 102 and 0.82 for Aerosil 200.

Flow properties

Table 10: Flow properties of powder.

Formulation code Bulk

density (ml)

Tapped

density

Carr,s

index

Hausner,s

ratio

Angle of

repose

L1 0.405 0.486 16.667 1.2 26.79896

L2 0.386 0.507 23.810 1.313 19.83887

L3 0.337 0.53 36.364 1.571 38.21645

L4 0.373 0.538 30.769 1.444 29.14671

L5 0.354 0.547 35.294 1.545 38.21645

L6 0.324 0.499 35 1.538 45.08278

L7 0.360 0.516 30.303 1.435 43.29119

L8 0.345 0.518 33.333 1.5 33.28762

L9 0.337 0.505 33.333 1.5 29.37036

L10 0.433 0.65 33.333 1.5 48.83859

L11 0.381 0.529 28 1.389 20.91459

L12 0.359 0.501 28.333 1.395 31.30083


1062


Discussion– The flow properties of the liquisolid granules are very important for the

performance of the capsule. Thus the flow properties were analyzed before the capsule

filling. The compressibility index (≤33.33), Hauners ratio (≤1.571) and angle of repose

(≤48.89) values show a fairly excellent flowability of granules is shown in (Table 10).

On the basis of characterization of liquisolid drug we decide L1 formulation for proceeded

for further study because L1 formulation show better flow property as compare to other

formulations.

Evaluation of liquisolid compact

General appearance-All the liquisolid capsule was exhibits in cylindrical in shape with

hemispherical ends, odorless, and tasteless.

Weight variation- The weight of liquisolid capsules was measured by using digital balance

machine.

formulation code weight variation(mg)

L-1 957.75±0.085

Drug Content

Table 11: Drug content of the formulation.

Discussion: Table no. 11 revealed that the percentage of drug content was found in a range of

70.58±0.58 to 86.35±0.96. L1 showed maximum drug content (86.35±0.96) as well as

excellent flow properties. So, optimized formulation (L1) proceeded for analytical study and

in vitro release study.

Formulation code Drug content (%)

L1 86.35±0.96

L2 86.28±0.4

L3 78.65±0.77

L4 80.83±0.48

L5 70.58±0.58

L6 72.95±0.22

L7 77.37±0.78

L8 84.49±0.40

L9 72.31±0.58

L10 82.63±0.62

L11 74.62±0.19

L12 76.60±0.62


1063


FTIR Studies of optimized formulation (L1)

Figure 7: FTIR spectrum of optimized formulation (L1).

All the spectrum peaks revealed that corresponding peaks of drugs are present in the above

spectra along with excipients peaks. Hence no interaction was noticed in the L1 formulation.

In vitro release studies

In vitro dissolution is used to find out the amount of drug released into system or medium at

an exacting period. Drug release graph for pure drug suspension and drug- loaded liquisolid

formulation (L1) as shown in Figure. Drug-loaded Liquisolid Formulation (L1) contained

excellent characteristic compare to pure drug. In the case of liquisolid formulation, about

98.13% of the liquisolid drug was released in the medium within 60 minutes. Apart from it,

the in vitro release of the pure drug showed very less drug release within 60 minutes in

comparison to drug liquisolid formulation (L1) (Table 12 and Figure 8).


1064


Table 12: In vitro release profile of pure drug suspension and drug-loaded liquisolid

formulation (L1). In vitro data profile.

Time(minutes) % Drug release of pure drug % Drug release of formulation

5 1.37±0.06 34.38±0.36

15 3.82±0.05 58.38±0.53

30 5.22±0.03 82.62±0.53

45 7.43±0.05 93.35±0.44

60 9.73±0.06 98.13±0.46

Figure 8: In vitro release profile comparison between pure drug and optimized drug.

In vitro release Kinetics

Data of in vitro drug release kinetic study of formulation (L1) was given below.

Zero-order kinetics models

Figure 9: Zero order graph of formulation (L1).


1065


First-Order kinetics model

Figure 10: First order graph of formulation (L1).

Higuchi kinetics model

Figure 11: Higuchi order graph of formulation (L1).

Korsmeyer peppas kinetics model

Figure 12: Korsmeyer peppas order graph of formulation (L1).

Table 13: Kinetic equation parameter of formulation (L1).

Formulation Zero order First order Higuchi Peppas

name R2 K0 R

2 K0 R

2 K0 R

2 K0

celecoxib 0.843 1.493 0.992 -0.027 0.970 11.92 0.987 0.435


1066


The data obtained for in vitro release shows in Table 13 were fixed into the equation for the

zero order, first order, Higuchi, Korsmeyer peppas models. The interpretation of data was

based on the data of the resulting regression coefficients.

The best fit model first orders the system where the drug release very fast manner as percent

cube root remaining drug releases Vs time. The value of R2 was found to be 0.992 maximum

for the first order kinetic model.

CONCLUSION

In the present investigation, we have designed a liquisolid compact of celecoxib to enhance

the solubility, dissolution time, bioavailability, the onset of action. Liquisolid compacts

involve improved bioavailability and dissolution rate due to the improved surface area and

wetting properties. On physicochemical evaluation, melting point of Celecoxib was found to

be 152˚C±0.279 °C. On UV spectrophotometer analysis absorption maxima was found to be

252 nm in methanol. Drug was highly soluble in nonsolvent substances like PEG 400, SPAN

20, PEG 200. The partition coefficient of Celecoxib in n-octanol: water was found to be

3.321±0.477 this indicated that the drug is Lipophilic in nature. FTIR spectroscopy analysis

shows no interaction between celecoxib formulation and excipients.

In vitro drug release of celecoxib liquisolid compacts showed improved the dissolution rate

as compared to pure Celecoxib drug. So PEG 400 can be an economical substitute as a

dissolution enhancing agent. Apart from it, increase solvent concentration dissolution was

improved. Based on arithmetic data revealed from the model, the data of release was best

fitted with first order kinetics. Hence from all aspects; we concluded that the release of drug

Celecoxib can be fast dissolving by proper designing of the formulation and selection of a

suitable method of preparation. Results shown L1 formulation considered as the optimum

formulation to design liquisolid compacts.

ACKNOWLEDGEMENT

The author highly thankful to Dr.Sarvesh Jain Malviya and his team of Oniosome Healthcare

Pvt. Ltd. The author acknowledge about research support provided by Oniosome Healthcare

Pvt. Ltd.


1067


REFERENCES

1. Vajir S, Sahu V, Ghuge N, Bakde BV. Liquisolid compact: a new technique for

enhancement of drug dissolution. Int J Pharm Res Dev, 2012; 4: 302-6.

2. Sowmya C, Reddy CS, Anilkumar D, Amrutha V, Anusha AL. Liquisolid technique: A

novel approach to enhance solubility and bioavailability of BCS II drugs. Int Res J

Pharm, 2012; 3: 108-15.

3. Sanka Krishna, Sravanthi Poienti, Abdul Bari Mohd, Prakash V Diwan. Improved oral

delivery of clonazepam through Liquisolid powder compact formulation: in vitro and ex

vivo characterization. Powder Technol, 2014; 256: 336-44.

4. Yousef Javadzadeh ab, Baharak Jafari Navimipour b and Ali Nokhodchi bc. Liquisolid

Technique for Dissolution Rate Enhancement of a High Dose Water-Insoluble Drug

(carbamazepine). International journal of pharmaceutics, 2007; 341: 26–34.

5. Spireas S and Bolton M. Liquisolid Systems and Methods of Preparing Same. U.S. Patent

5968, 1999; 550.

6. Fujicalin. Unique Spray Dried Carrier for Liquisolid Systems. www.fujichemical.co.jp

[email protected] (Accessed Jan 23), 2004.

7. Bhise SB, Nighute AB, Yadav AV, YadavVB, “Acelofenac Size enlargement by non

Aqueous granulation with Improved solubility and Dissolution,” Arch Pharm Sci. & Res.,

2009; 1: 115-122.

8. “Liquisolid Technique For Solubility Enhancement” Review Article, Ekta Lalasaheb

Jadhav, and Rachel Geeverghese, World Journal of Pharmaceutical Research, 2015; 4(4):

1756-1767.

9. Lachman leon, lieberman Herbert, kanig joseph, the theory and practice of industrial

pharmacy, 3rd

edition, varghese publishing house, dadar, 1987; 296-310.

Date post:	11-Dec-2021
Category:	Documents
Upload:	others
View:	6 times
Download:	1 times

TO OPTIMIZED THE DISSOLUTION AND SOLUBILITY PROPERTY …

Documents